Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Hongzhang Shen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1275-2862; OpenAlex author ID A5053348244, A5125484962. Sources: OpenAlex.

Their work

Papers
11 (first author 4, last author 4)
Trials
0
Grants
0
Labs led
2
Collaborators
14
Papers, trials and grants by year

2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 11

  1. Palmaturbine Inhibits Pancreatic Ductal Adenocarcinoma by Suppressing the JAK2/STAT3 Signaling Pathway. Co-author DOI 10.3390/ijms27041707↗
  2. Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated degradation. Last author DOI 10.1016/j.phymed.2025.157245↗
  3. Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial. First author DOI 10.4251/wjgo.v17.i4.103311↗
  4. Advances in pancreatic cancer epigenetics: From the mechanism to the clinic. First author DOI 10.4251/wjgo.v17.i7.106238↗
  5. Hyperthermia improves gemcitabine sensitivity of pancreatic cancer cells by suppressing the EFNA4/β-catenin axis and activating dCK. Co-author DOI 10.1016/j.heliyon.2024.e28488↗
  6. Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and trigger endoplasmic reticulum stress. Last author DOI 10.1016/j.intimp.2024.113497↗
  7. Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis. Last author DOI 10.1016/j.bcp.2023.115810↗
  8. Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signaling Pathway. Last author DOI 10.1155/2022/8675096↗
  9. The Role of Feedback Loops in Targeted Therapy for Pancreatic Cancer. First author DOI 10.3389/fonc.2022.800140↗
  10. Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in vitro. First author DOI 10.7150/jca.65875↗
  11. The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-021-04387-z↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaofeng Zhang · 7 shared papers, 2022–2025 · strength 1.63
  2. Dongchao Xu · 7 shared papers, 2021–2026 · strength 1.62
  3. Mengyao Tian · 3 shared papers, 2022–2024 · strength 0.59
  4. Qiang Liu · 3 shared papers, 2022–2024 · strength 0.58
  5. Jia-Dan Zhou · 1 shared paper, 2025 · strength 0.54
  6. Yulian Wu · 1 shared paper, 2026 · strength 0.43
  7. Weigang Gu · 2 shared papers, 2022–2024 · strength 0.43
  8. Hangbin Jin · 1 shared paper, 2025 · strength 0.33
  9. Min-Hui Sun · 1 shared paper, 2025 · strength 0.33
  10. Hangbin Jin · 1 shared paper, 2024 · strength 0.23
  11. Qiaoxian He · 1 shared paper, 2024 · strength 0.23
  12. Jianfeng Yang · 1 shared paper, 2022 · strength 0.20
  13. Meidan Ying · 1 shared paper, 2023 · strength 0.19
  14. Juanjuan Zhu · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.